Elucidating the role of GS-gpcr signaling at the bone-vascular interface
Active Grant Awarded
- Award ID
- R56DE035489
- Recipient
-
Northern California Institute For Research And Education, Inc. UEI NJZEFMRACCH9
- Awarding agency
-
National Institute of Dental and Craniofacial Research
National Institutes of Health, Department of Health and Human Services
- Obligated
- $499,022
Award facts
- Assistance listing
- 93.121 Oral Diseases and Disorders Research
- Completion date 27% complete
- Place of performance
- San Francisco, CA 94121, USA
Award details come from USAspending.gov.
About this award
The U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Dental and Craniofacial Research awarded Northern California Institute For Research And Education, Inc. (doing business as NCIRE) $499,022 on August 13, 2026, under Assistance Listing 93.121, Oral Diseases and Disorders Research, through grant R56DE035489. The grant funds research on how GS-GPCR signaling in endothelial and perivascular cells contributes to osteogenesis and fibrosis, using fibrous dysplasia of bone as a disease model. The ultimate completion date is August 14, 2027, and the place of performance is San Francisco, California.
NCIRE passes part of the work to the University of California, Davis, under sub-award R56DE035489-WEN3309-01, dated October 27, 2026. The sub-award's Fierro lab will transduce endothelial cells with GNASWT, GNASR201H, or GNASR201C lentiviruses and test them in tube formation, wound/scratch, and Matrigel plug assays. It will also run transwell co-culture with bone marrow-derived mesenchymal stromal cells, measuring alkaline phosphatase activity, osteogenic marker expression, and mineralization. Finally, it will conduct in vivo angiogenesis and ectopic bone formation experiments in HA/PLG scaffolds, assessed by microCT and immunohistochemistry.
Description
- Abstract
- Skeletal diseases contribute significantly to morbidity, yet limited therapies exist for building new bone. Understanding the molecular mechanisms driving bone formation is critical for improving skeletal health across the lifespan. GS-gpcr signaling is a major driver of bone formation, and activating this pathway using recombinant parathyroid hormone (PTH) is an effective treatment strategy for osteoporosis, fractures, and skeletal dysplasias. The anabolic effect of GS-gpcr activation in osteogenic lineages is well-established, but its role in non-osteogenic cells in the bone niche is poorly understood. There is compelling evidence that cells comprising the bone vasculature play an integral role in skeletal development, maintenance, and repair, yet the role of GS-gpcr signaling in these lineages and the effect on osteogenesis has not been studied. Fibrous dysplasia of the bone (FD) is a prototypical disease of constitutive GS-gpcr signaling that leads to expansile, fibrotic bone lesions and massive trabecular bone growth. We and others have used FD as a disease model to delineate the mechanisms by which GS-gpcr activation in osteogenic lineages drives bone formation. The long- standing paradigm has been that GS-gpcr signaling in osteoprogenitors drives fibrosis and aberrant osteogenesis in FD. Single-cell RNA sequencing data from human FD bone lesions shows that in addition to osteogenic lineages, endothelial and perivascular cells also harbor GNASR201H/C mutations and express an altered, fibrotic transcriptome. This unexpected finding suggests that GS-gpcr signaling in vascular cell lineages may contribute to the dramatic FD phenotype and may regulate bone formation more broadly. The overall objective of this proposal is to elucidate the molecular mechanisms by which GS-gpcr signaling in endothelial and perivascular cells contribute to osteogenesis and fibrosis, using FD as a disease model. Our central hypothesis is that GS-gpcr signaling in endothelial and perivascular lineages activates critical signaling pathways downstream of GSA, including vegf, WNT/ B-catenin and TGF B/BMP that promote fibrosis and osteogenesis. To test this hypothesis, we implement human induced pluripotent stem cell (HIPSC) models, primary human cells and tissue, and murine models to elucidate the role of GS-gpcr signaling at the bone- vascular interface. Detailed knowledge of the signaling pathways activated at the bone-vascular interface will help elucidate the mechanisms by which GS-gpcr signaling in non-skeletal lineages contribute to bone formation. This knowledge can then be leveraged to develop new therapeutics for diseases of impaired osteogenesis, including osteoporosis, fracture repair, and skeletal dysplasias.
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| University Of California, Davis | $120,750 |
Quick answers
Who received award R56DE035489?
R56DE035489 was awarded to Northern California Institute For Research And Education, Inc. by National Institute of Dental and Craniofacial Research (National Institutes of Health) on August 13, 2026.
How much is award R56DE035489 worth?
$499,022 has been obligated on R56DE035489.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award